Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö.

Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.

PMID:
28678784
2.

Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study.

Hlavatý J, Tonar Z, Renner M, Panitz S, Petznek H, Schweizer M, Schüle S, Kloke BP, Moldzio R, Witter K.

Histochem Cell Biol. 2017 Sep;148(3):313-329. doi: 10.1007/s00418-017-1569-1. Epub 2017 Apr 10.

3.

Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.

Theelen J, Braun J, Hörzer H, Kloke BP, Ott M, Pizzitola I, Schirmer U, Miller M.

Cancer Immunol Immunother. 2017 May;66(5):673-681. doi: 10.1007/s00262-017-1974-2. Epub 2017 Mar 1. No abstract available.

PMID:
28251274
4.

Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.

Zhang Z, Gu Q, Jaguva Vasudevan AA, Hain A, Kloke BP, Hasheminasab S, Mulnaes D, Sato K, Cichutek K, Häussinger D, Bravo IG, Smits SH, Gohlke H, Münk C.

Retrovirology. 2016 Jul 1;13(1):46. doi: 10.1186/s12977-016-0274-9.

5.

The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015.

Miller M, Jahndel V, Kutscher S, Mahr A, Rae R, Kloke BP.

Cancer Immunol Immunother. 2016 Oct;65(10):1277-87. doi: 10.1007/s00262-016-1850-5. Epub 2016 Jun 3. No abstract available.

PMID:
27259506
6.

Actively personalized cancer vaccines--the step into clinical application.

Kloke BP, Kreiter S, Vormehr M, Diken M, Kuhn AN, Sahin U.

Pharmazie. 2016 Jan;71(1):43-7. Review.

PMID:
26867352
7.

Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format.

Diken M, Kreiter S, Kloke B, Sahin U.

Prog Tumor Res. 2015;42:44-54. doi: 10.1159/000437184. Epub 2015 Sep 4. Review.

PMID:
26383626
8.

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.

Kloke BP, Mahr A, Jabulowsky RA, Kutscher S, Rae R, Britten CM.

Cancer Immunol Immunother. 2015 Jul;64(7):923-30. doi: 10.1007/s00262-014-1643-7. Epub 2014 Dec 30. No abstract available.

PMID:
25548093
9.

Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.

Kloke BP, Rae R, Mahr A, Burkhardt UE, Kvistborg P, Britten CM.

Cancer Immunol Immunother. 2014 Jul;63(7):749-55. doi: 10.1007/s00262-013-1495-6. Epub 2013 Nov 5. No abstract available.

PMID:
24190545
10.

Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.

Kloke BP, Kutscher S, Rae R, Kvistborg P, Britten CM, Hadrup SR.

Cancer Immunol Immunother. 2013 May;62(5):975-81. doi: 10.1007/s00262-012-1386-2. Epub 2013 Jan 9. No abstract available.

PMID:
23299564
11.

IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.

Burkhardt UE, Sloots A, Jakobi V, Wei WZ, Cavallo F, Kloke BP, Wels WS.

Cancer Immunol Immunother. 2012 Sep;61(9):1473-84. doi: 10.1007/s00262-012-1215-7. Epub 2012 Feb 14.

PMID:
22331080
12.

Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Grabski E, Waibler Z, Schüle S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U.

Mol Biotechnol. 2011 Mar;47(3):262-9. doi: 10.1007/s12033-010-9340-z.

PMID:
20938757
13.

Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.

Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M.

J Gene Med. 2010 May;12(5):446-52. doi: 10.1002/jgm.1454.

PMID:
20440755
14.

Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj.

Schüle S, Kloke BP, Kaiser JK, Heidmeier S, Panitz S, Wolfrum N, Cichutek K, Schweizer M.

PLoS One. 2009 Sep 21;4(9):e7098. doi: 10.1371/journal.pone.0007098.

15.

Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Perkovic M, Schmidt S, Marino D, Russell RA, Stauch B, Hofmann H, Kopietz F, Kloke BP, Zielonka J, Ströver H, Hermle J, Lindemann D, Pathak VK, Schneider G, Löchelt M, Cichutek K, Münk C.

J Biol Chem. 2009 Feb 27;284(9):5819-26. doi: 10.1074/jbc.M808853200. Epub 2008 Dec 12.

16.

Multiple restrictions of human immunodeficiency virus type 1 in feline cells.

Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg M, Bonci F, Pistello M, Löchelt M, Cichutek K.

J Virol. 2007 Jul;81(13):7048-60. Epub 2007 Apr 25.

17.

Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.

Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M.

Virology. 2007 Aug 1;364(2):330-41. Epub 2007 Apr 5.

Supplemental Content

Support Center